Skip to main content
. 2023 May 23;4(6):101053. doi: 10.1016/j.xcrm.2023.101053

Figure 7.

Figure 7

Comparison of CAR-TRM cell differentiation methods

(A) RUNX3 expression measured in various anti-mesothelin SS1 CAR T cell products: standard T cell medium culture (control CAR T), standard T cell medium supplemented with TGF-β (TGF-β CAR T) and engineered to overexpress RUNX3 (RUNX3 OE CAR T) (MFI, geometric mean fluorescence intensity).

(B) TRM (CD103, CD39, CD49a) and activation (CD25) markers were assessed after CAR T cell manufacturing.

(C) NSG mice (n = 7 biological replicates per group) were injected with the EMMESO cell line. Once tumors reached a size of ∼120 mm3, mice received a single dose of 1 × 107 SS1 CAR T cells. Activated non-transduced T cells served as a negative control. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant (one-way ANOVA).